Ongoing clinical trials with DOACs in patients with CVT
| Title . | Study type . | Intervention . | Main outcome . | No. of patients . | Start date . | Recruitment status . |
|---|---|---|---|---|---|---|
| A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT) (NCT02913326) | Interventional (phase 3), randomized, parallel assignment, open label | Dabigatran etexilate vs warfarin for 6 mo | Composite rate of major bleeding and venous thromboembolism | 120 | 13 Dec 2016 | Completed |
| The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis (NCT03217448) | Interventional (phase 3), randomized, parallel assignment, open label, single blind (outcomes assessor) | Dabigatran etexilate vs warfarin for 6 mo | Recanalization after 6 mo | 80 | 30 Oct 2017 | Recruiting |
| Comparison of the Efficacy of Rivaroxaban to Coumadin (Warfarin) in Cerebral Venous Thrombosis (NCT03191305) | Interventional, nonrandomized, parallel assignment, single blind (participants) | Rivaroxaban vs warfarin | Hemorrhage or recurrent CVT based on repeated MRI at 6 mo | 50 | — | Not yet recruiting |
| Study of Rivaroxaban for CeREbral Venous Thrombosis (SECRET) (NCT03178864) | Interventional (phase 2), randomized, parallel assignment, open label, single blind (outcomes assessor) | Rivaroxaban vs standard of care | Composite rate of all-cause mortality, symptomatic intracranial bleeding, and major extracranial bleeding at 6 mo | 380 | 12 Mar 2019 | Recruiting |
| Comparing Treatment Outcomes in CVT Patients Who Were Treated With Warfarin and Rivaroxaban in Isfahan, Iran (NCT03747081) | Interventional (phase 1/2), randomized, parallel assignment, open label | Rivaroxaban vs warfarin for 3 mo | Modified Rankin scale at 3 mo | 50 | 1 Sep 2018 | Recruiting |
| Title . | Study type . | Intervention . | Main outcome . | No. of patients . | Start date . | Recruitment status . |
|---|---|---|---|---|---|---|
| A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT) (NCT02913326) | Interventional (phase 3), randomized, parallel assignment, open label | Dabigatran etexilate vs warfarin for 6 mo | Composite rate of major bleeding and venous thromboembolism | 120 | 13 Dec 2016 | Completed |
| The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis (NCT03217448) | Interventional (phase 3), randomized, parallel assignment, open label, single blind (outcomes assessor) | Dabigatran etexilate vs warfarin for 6 mo | Recanalization after 6 mo | 80 | 30 Oct 2017 | Recruiting |
| Comparison of the Efficacy of Rivaroxaban to Coumadin (Warfarin) in Cerebral Venous Thrombosis (NCT03191305) | Interventional, nonrandomized, parallel assignment, single blind (participants) | Rivaroxaban vs warfarin | Hemorrhage or recurrent CVT based on repeated MRI at 6 mo | 50 | — | Not yet recruiting |
| Study of Rivaroxaban for CeREbral Venous Thrombosis (SECRET) (NCT03178864) | Interventional (phase 2), randomized, parallel assignment, open label, single blind (outcomes assessor) | Rivaroxaban vs standard of care | Composite rate of all-cause mortality, symptomatic intracranial bleeding, and major extracranial bleeding at 6 mo | 380 | 12 Mar 2019 | Recruiting |
| Comparing Treatment Outcomes in CVT Patients Who Were Treated With Warfarin and Rivaroxaban in Isfahan, Iran (NCT03747081) | Interventional (phase 1/2), randomized, parallel assignment, open label | Rivaroxaban vs warfarin for 3 mo | Modified Rankin scale at 3 mo | 50 | 1 Sep 2018 | Recruiting |
MRI, magnetic resonance imaging.